Post by Synendos Therapeutics AG

A proud moment for Synendos Therapeutics AG at the INTERNATIONAL CANNABINOID RESEARCH SOCIETY 2026 in Dijon, France. Three of our team present at the conference, representing the cutting edge of endocannabinoid research: 🎤 Prof. Jürg Gertsch delivered the Presidential Plenary Lecture: A Druggable ACSL4 Isoform Moonlighting Function Facilitates Endocannabinoid Plasma-membrane Diffusion and Tunes CB1 Receptor Signaling 🔬 Dr. Andrea Chicca presented compelling data on SYT-510, our clinical candidate for a first-in-class selective endocannabinoid reuptake inhibitor (SERI), demonstrating efficacy across multiple preclinical CNS disease models and a favorable Phase 1 safety profile — with Phase 2 now underway 📋 Dr. Celine Maeder showcased Synendos’ research at the poster session, sparking great discussions with fellow scientists from around the world. We are deeply grateful to the ICRS community for the opportunity to share our science and connect with leading researchers in the field. #Endocannabinoid #ICRS #SERIs #Neuroscience #Synendos #MentalHealth